Lily E Johnston1, Emily A Downs1, Robert B Hawkins1, Mohammed A Quader2, Alan M Speir3, Jeffrey B Rich4, Ravi K Ghanta1, Leora T Yarboro1, Gorav Ailawadi5. 1. Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Virginia, Charlottesville, Virginia. 2. Division of Cardiothoracic Surgery, Virginia Commonwealth University, Richmond, Virginia. 3. Inova Heart and Vascular Institute, Inova Fairfax Hospital, Fairfax, Virginia. 4. MidAtlantic Cardiothoracic Surgeons, Norfolk, Virginia. 5. Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Virginia, Charlottesville, Virginia. Electronic address: gorav@virginia.edu.
Abstract
BACKGROUND: Two large, randomized trials are underway evaluating transcatheter aortic valve replacement (AVR) against conventional surgical AVR. We analyzed contemporary, real-world outcomes of surgical AVR in low-risk patients to provide a practical benchmark of outcomes and cost for evaluating current and future transapical AVR technology. METHODS: From 2010 to 2015, 2,505 isolated AVR operations were performed for severe aortic stenosis at 18 statewide cardiac institutions. Of these, 2,138 patients had a Society of Thoracic Surgeons predicted risk of mortality of less than 4%, and 1,119 met other clinical and hemodynamic criteria as outlined in the PARTNER 3 (The Placement of Transcatheter Aortic Valves) protocol. Patients with endocarditis, end-stage renal disease, ejection fraction of less than 0.45, bicuspid valves, and previous valve replacements were excluded. Outcomes of interest included operative death and postoperative adverse events. RESULTS: The median Society of Thoracic Surgeons predicted risk of mortality for the study-eligible patients was 1.44%, with a median age of 72 years (interquartile range [IQR], 65 to 78 years). Operative mortality was 1.3%, permanent stroke was 1.3%, and pacemaker requirement was 4.2%. The most common adverse events were transfusion of 2 or more units of red blood cells (18%) and atrial fibrillation (28%). The median length of stay was 6 days (IQR, 5 to 8 days). Median total hospital cost was $37,999 (IQR, $30,671 to $46,138). Examination of complications by age younger than 65 vs 65 or older demonstrated a significantly lower need for transfusion (11.2%, p < 0.001) and incidence of atrial fibrillation (17.1%, p < 0.001) but no difference in operative mortality (2.2% vs 0.9%, p = 0.1), major morbidity (10.4% vs 12.6%, p = 0.3), or total hospital costs. CONCLUSIONS: Low-risk patients undergoing surgical AVR in the current era have excellent results. The most common complications were atrial fibrillation and bleeding. These real-world results should provide additional context for upcoming transcatheter clinical trial data.
BACKGROUND: Two large, randomized trials are underway evaluating transcatheter aortic valve replacement (AVR) against conventional surgical AVR. We analyzed contemporary, real-world outcomes of surgical AVR in low-risk patients to provide a practical benchmark of outcomes and cost for evaluating current and future transapical AVR technology. METHODS: From 2010 to 2015, 2,505 isolated AVR operations were performed for severe aortic stenosis at 18 statewide cardiac institutions. Of these, 2,138 patients had a Society of Thoracic Surgeons predicted risk of mortality of less than 4%, and 1,119 met other clinical and hemodynamic criteria as outlined in the PARTNER 3 (The Placement of Transcatheter Aortic Valves) protocol. Patients with endocarditis, end-stage renal disease, ejection fraction of less than 0.45, bicuspid valves, and previous valve replacements were excluded. Outcomes of interest included operative death and postoperative adverse events. RESULTS: The median Society of Thoracic Surgeons predicted risk of mortality for the study-eligible patients was 1.44%, with a median age of 72 years (interquartile range [IQR], 65 to 78 years). Operative mortality was 1.3%, permanent stroke was 1.3%, and pacemaker requirement was 4.2%. The most common adverse events were transfusion of 2 or more units of red blood cells (18%) and atrial fibrillation (28%). The median length of stay was 6 days (IQR, 5 to 8 days). Median total hospital cost was $37,999 (IQR, $30,671 to $46,138). Examination of complications by age younger than 65 vs 65 or older demonstrated a significantly lower need for transfusion (11.2%, p < 0.001) and incidence of atrial fibrillation (17.1%, p < 0.001) but no difference in operative mortality (2.2% vs 0.9%, p = 0.1), major morbidity (10.4% vs 12.6%, p = 0.3), or total hospital costs. CONCLUSIONS: Low-risk patients undergoing surgical AVR in the current era have excellent results. The most common complications were atrial fibrillation and bleeding. These real-world results should provide additional context for upcoming transcatheter clinical trial data.
Authors: Matthew R Reynolds; Elizabeth A Magnuson; Kaijun Wang; Yang Lei; Katherine Vilain; Joshua Walczak; Susheel K Kodali; John M Lasala; William W O'Neill; Charles J Davidson; Craig R Smith; Martin B Leon; David J Cohen Journal: Circulation Date: 2012-02-03 Impact factor: 29.690
Authors: David S Bach; Derrick Siao; Steven E Girard; Claire Duvernoy; Benjamin D McCallister; Sarah K Gualano Journal: Circ Cardiovasc Qual Outcomes Date: 2009-10-27
Authors: Lars G Svensson; Murat Tuzcu; Samir Kapadia; Eugene H Blackstone; Eric E Roselli; A Marc Gillinov; Joseph F Sabik; Bruce W Lytle Journal: J Thorac Cardiovasc Surg Date: 2013-03 Impact factor: 5.209
Authors: Damien J LaPar; Ivan K Crosby; Gorav Ailawadi; Niv Ad; Elmer Choi; Bruce D Spiess; Jeffery B Rich; Vigneshwar Kasirajan; Edwin Fonner; Irving L Kron; Alan M Speir Journal: J Thorac Cardiovasc Surg Date: 2013-03 Impact factor: 5.209
Authors: Gorav Ailawadi; Damien J LaPar; Alan M Speir; Ravi K Ghanta; Leora T Yarboro; Ivan K Crosby; D Scott Lim; Mohammed A Quader; Jeffrey B Rich Journal: Ann Thorac Surg Date: 2015-09-26 Impact factor: 4.330
Authors: Vinod H Thourani; Rakesh M Suri; Rebecca L Gunter; Shubin Sheng; Sean M O'Brien; Gorav Ailawadi; Wilson Y Szeto; Todd M Dewey; Robert A Guyton; Joseph E Bavaria; Vasilis Babaliaros; James S Gammie; Lars Svensson; Mathew Williams; Vinay Badhwar; Michael J Mack Journal: Ann Thorac Surg Date: 2014-11-14 Impact factor: 4.330
Authors: Mary Ann Clark; Suzanne V Arnold; Francis G Duhay; Ann K Thompson; Michelle J Keyes; Lars G Svensson; Robert O Bonow; Benjamin T Stockwell; David J Cohen Journal: Circ Cardiovasc Qual Outcomes Date: 2012-09-04